Epidemiology, health policy and outcomes
Karen Costenbader, MD, MPH
Brigham and Women's Hospital/ Harvard Medical School
BOSTON, MA, United States
Disclosure(s): Bristol-Myers Squibb(BMS): Consultant (Ongoing); Cabaletta: Consultant (Ongoing); Gilead: Grant/Research Support (Ongoing); Glaxo Smith Kline: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Merck/MSD: Grant/Research Support (Ongoing)
April Jorge, MD
Massachusetts General Hospital
Medford, MA, United States
Disclosure(s): Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing); Cabaletta Bio: Site Co-Investigator for a clinical trial (Ongoing)
In the general population, use of two new classes of novel oral hypoglycemic agents, originally developed for the treatment of type II diabetes, are showing an increasing number of strong off-target beneficial effects. Widely used for type II diabetes, as well as weight reduction, both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1) have been found to decrease cardiovascular disease and prevent progression of chronic kidney disease. These recent results and indications for using these medications in type II diabetes, obesity, and prevention of cardiovascular and renal disease will be reviewed, as will evidence of central nervous system effects related to potential analgesic effects and efficacy of GLP-1 that may be relevant to treatment of arthritis.
Speaker: LOUIS ARONNE, MD – Weill Cornell Medicine
Speaker: Brittany Weber, MD;PhD – Brigham and Women's Hospital
Speaker: Isabelle Ayoub, MD – The Ohio State University